Webb5 juni 2024 · Ibrexafungerp, also known as SCY-078 or MK-3118, is a novel enfumafungin derivative oral triterpene antifungal approved for the treatment of vulvovaginal candidiasis (VVC), also known as a vaginal yeast infection. 1, 9 It was developed out of a need to treat fungal infections that may have become resistant to echinocandins or azole antifungals. … Webb22 apr. 2024 · The lead molecule SCY-078 (ibrexafungerp) is an orally active synthetic derivative of enfumifungin with in vitro antifungal activity. In vivo, ibrexafungerp is extensively distributed in the tissue and is active against Candida and Aspergillus species [ 8 ].
Antifungal Resistance and the Role of New Therapeutic Agents
WebbDescription: Ibrexafungerp, also known as MK3118 or SCY078, is a glucan synthase inhibitor potentially for the treatment of candida infection and aspergillosis. … WebbSCY-078 (Ibrexafungerp;MK-3118;MK 3118;SCY 078) Catalog No.: PC-60411 Not For Human Use, Lab Use Only. Ibrexafungerp (MK 3118, SCY-078) is a novel orally bioavailable fungal beta-1,3-D glucan synthetase inhibitor against Candida species C. glabrata (MIC 0.03 to 0.25 ug/ml), C. parapsilosis (MIC 0.06 to 0.25 ug/ml). homefin loan
Ibrexafungerp citrate – Drug Approvals International
Webb12 jan. 2024 · Among agents that target the cell wall, 2 glucan synthesis inhibitors are discussed (rezafungin and ibrexafungerp), as well as fosmanogepix and nikkomycin Z. Agents that target the cell membrane include 3 fourth-generation azoles, oral encochleated amphotericin B, and aureobasidin A. Webb20 okt. 2016 · Ibrexafungerp acts similarly to the echinocandin antifungals, by inhibiting the synthesis of β-1,3-glucan synthase. 1, 9 While echinocandins bind to the FKS1 … WebbExpert opinion: Ibrexafungerp demonstrates potent in vitro activity against susceptible and resistant Candida species, including echinocandin-resistant C. glabrata and multidrug … homefinity rating